The role of adiponectin in metabolic and vascular disease: A review

Clinical Nephrology

Volumn 75, Issue 1, 2011, Pages 26-33

  Cui, J ^a   Panse, S ^a   Falkner, B ^a  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Adiponectin; Chronic kidney disease (CKD); Insulin; Obesity

Indexed keywords

ADIPONECTIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; RIMONABANT;

ADIPOSE TISSUE; ALBUMINURIA; CALORIC RESTRICTION; CHRONIC KIDNEY DISEASE; DIET SUPPLEMENTATION; HUMAN; HYPERTENSION; INSULIN RESISTANCE; KIDNEY TRANSPLANTATION; LEAN BODY WEIGHT; METABOLIC DISORDER; NONHUMAN; OBESITY; REVIEW; SMOKING CESSATION; VASCULAR DISEASE; WEIGHT REDUCTION;

ADIPONECTIN; ADIPOSE TISSUE; ANIMALS; BIOLOGICAL MARKERS; HUMANS; HYPERTENSION; INSULIN RESISTANCE; KIDNEY DISEASES; METABOLIC DISEASES; OBESITY; VASCULAR DISEASES;

EID: 79251503314     PISSN: 03010430     EISSN: None     Source Type: Journal    
DOI: 10.2379/CNP75026     Document Type: Review

References (82)

1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM. Positional cloning of the mouse obese gene and its human homologue. Nature. 1994; 372: 425-432.
2. Hotamisligil GS, Shargill NS, Spiegelman BM. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science. 1993; 259: 87-91.
3. Shimomura I, Funahashi T, Takahashi M, Maeda K, Kotani K, Nakamura T et al. Enhanced expression of PAI-1 in visceral fat: possible contributor to vascular disease in obesity. Nat Med. 1996; 2: 800-803.
4. Qi Y, Takahashi N, Hileman SM, Patel HR, Berg AH, Pajvani UB et al. Adiponectin acts in the brain to decrease body weight. Nat Med. 2004; 10: 524-529.
5. Iacobellis G, Pistilli D, Gucciardo M, Leonetti F, Miraldi F, Brancaccio G et al. Adiponectin expression in human epicardial adipose tissue in vivo is lower in patients with coronary artery disease. Cytokine. 2005; 29: 251-255.
6. Maeda K, Okubo K, Shimomura I, Mizuno K, Matsuzawa Y, Matsubara K. Analysis of an expression profile of genes in the human adipose tissue. Gene. 1997; 190: 227-235.
7. Shapiro L, Scherer PE. The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol. 1998; 8: 335-338.
8. Bogan JS, Lodish HF. Two compartments for insulin-stimulated exocytosis in 3T3-L1 adipocytes defined by endogenous ACRP30 and GLUT4. J Cell Biol. 1999; 146: 609-620.
9. Xie L, Boyle D, Sanford D, Scherer PE, Pessin JE, Mora S. Intracellular trafficking and secretion of adiponectin is dependent on GGA-coated vesicles. J Biol Chem. 2006; 281: 7253-7259.
10. Clarke M, Ewart MA, Santy LC, Prekeris R, Gould GW. ACRP30 is secreted from 3T3-L1 adipocytes via a Rab11-dependent pathway. Biochem Biophys Res Commun. 2006; 342: 1361-1367.
11. Waki H, Yamauchi T, Kamon J, Ito Y, Uchida S, Kita S et al. Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem. 2003; 278: 40352-40363.
12. Basu R, Pajvani UB, Rizza RA, Scherer PE. Selective downregulation of the high molecular weight form of adiponectin in hyperinsulinemia and in Type 2 diabetes: differential regulation from nondiabetic subjects. Diabetes. 2007; 56: 2174-2177.
13. Salani B, Briatore L, Andraghetti G, Adami GF, Maggi D, Cordera R. High-molecular weight adiponectin isoforms increase after biliopancreatic diversion in obese subjects. Obesity. (Silver Spring) 2006; 14: 1511-1514.
14. Tonelli J, Li W, Kishore P, Pajvani UB, Kwon E, Weaver C et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in Type 2 diabetes. Diabetes. 2004; 53: 1621-1629.
15. Pajvani UB, Hawkins M, Combs TP, Rajala MW, Doebber T, Berger JP et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004; 279: 12152-12162.
16. Lara-Castro C, Luo N, Wallace P, Klein RL, Garvey WT. Adiponectin multimeric complexes and the metabolic syndrome trait cluster. Diabetes. 2006; 55: 249-259.
17. Fisher FF, Trujillo ME, Hanif W, Barnett AH, McTernan PG, Scherer PE et al. Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia. 2005; 48: 1084-1087.
18. Araki S, Dobashi K, Kubo K, Asayama K, Shirahata A. High molecular weight, rather than total, adiponectin levels better reflect metabolic abnormalities associated with childhood obesity. J Clin Endocrinol Metab. 2006; 91: 5113-5116.
19. Fruebis J, Tsao TS, Javorschi S, Ebbets-Reed D, Erickson MR, Yen FT et al. Proteolytic cleavage product of 30-kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci. U S A2001; 98: 2005-2010.
20. Halleux CM, Takahashi M, Delporte ML, Detry R, Funahashi T, Matsuzawa Y et al. Secretion of adiponectin and regulation of apM1 gene expression in human visceral adipose tissue. Biochem Biophys Res Commun. 2001; 288: 1102-1107.
21. Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994; 43: 1271-1278.
22. Maeda N, Takahashi M, Funahashi T, Kihara S, Nishizawa H, Kishida K et al. PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes. 2001; 50: 2094-2099.
23. Yamauchi T, Kamon J, Ito Y, Tsuchida A, Yokomizo T, Kita S et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003; 423: 762-769.
24. Hug C, Wang J, Ahmad NS, Bogan JS, Tsao TS, Lodish HF. T-cadherin is a receptor for hexameric and high-molecular-weight forms of Acrp30/adiponectin. Proc Natl Acad Sci U S A. 2004; 101: 10308-10313.
25. Kadowaki T, Yamauchi T, Kubota N, Hara K, Ueki K, Tobe K. Adiponectin and adiponectin receptors in insulin resistance, diabetes, and the metabolic syndrome. J Clin Invest. 2006; 116: 1784-1792.
26. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem. 2003; 278: 45021-45026.
27. Yamauchi T, Kamon J, Minokoshi Y, Ito Y,Waki H, Uchida S et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002; 8: 1288-1295.
28. Tomas E, Tsao TS, Saha AK, Murrey HE, Zhang Cc C, Itani SI et al. Enhanced muscle fat oxidation and glucose transport by ACRP30 globular domain: acetyl-CoA carboxylase inhibition and AMP-activated protein kinase activation. Proc Natl Acad Sci U S A. 2002; 99: 16309-16313.
29. Ouchi N, Kihara S, Arita Y, Okamoto Y, Maeda K, Kuriyama H et al. Adiponectin, an adipocyte-derived plasma protein, inhibits endothelial NFkappaB signaling through a cAMP-dependent pathway. Circulation. 2000; 102: 1296-1301.
30. Yamamoto Y, Hirose H, Saito I, Tomita M, Taniyama M, Matsubara K et al. Correlation of the adipocyte-derived protein adiponectin with insulin resistance index and serum high-density lipoprotein-cholesterol, independent of body mass index, in the Japanese population. Clin Sci. (Lond) . 2002; 103: 137-142.
31. Weiss R, Dziura J, Burgert TS, Tamborlane WV, Taksali SE, Yeckel CW et al. Obesity and the metabolic syndrome in children and adolescents. N Engl J Med. 2004; 350: 2362-2374.
32. Weiss R, Dufour S, Groszmann A, Petersen K, Dziura J, Taksali SE et al. Low adiponectin levels in adolescent obesity: a marker of increased intramyocellular lipid accumulation. J Clin Endocrinol Metab. 2003; 88: 2014-2018.
33. Asayama K, Hayashibe H, Dobashi K, Uchida N, Nakane T, Kodera K et al. Decrease in serum adiponectin level due to obesity and visceral fat accumulation in children. Obes Res. 2003; 11: 1072-1079.
34. Stefan N, Bunt JC, Salbe AD, Funahashi T, Matsuzawa Y, Tataranni PA. Plasma adiponectin concentrations in children: relationships with obesity and insulinemia. J Clin Endocrinol Metab. 2002; 87: 4652-4656.
35. Bottner A, Kratzsch J, Muller G, Kapellen TM, Bluher S, Keller E et al. Gender differences of adiponectin levels develop during the progression of puberty and are related to serum androgen levels. J Clin Endocrinol Metab. 2004; 89: 4053-4061.
36. Mantzoros CS, Rifas-Shiman SL, Williams CJ, Fargnoli JL, Kelesidis T, Gillman MW. Cord blood leptin and adiponectin as predictors of adiposity in children at 3 years of age: a prospective cohort study. Pediatrics. 2009; 123: 682-689.
37. Degawa-Yamauchi M, Dilts JR, Bovenkerk JE, Saha C, Pratt JH, Considine RV. Lower serum adiponectin levels in African-American boys. Obes Res. 2003; 11: 1384-1390.
38. Statnick MA, Beavers LS, Conner LJ, Corominola H, Johnson D, Hammond CD et al. Decreased expression of apM1 in omental and subcutaneous adipose tissue of humans with Type 2 diabetes. Int J Exp Diabetes Res. 2000; 1: 81-88.
39. Tsuchida A, Yamauchi T, Ito Y, Hada Y, Maki T, Takekawa S et al. Insulin/Foxo1 pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004; 279: 30817-30822.
40. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Weight reduction increases plasma levels of an adipose-derived anti-inflammatory protein, adiponectin. J Clin Endocrinol Metab. 2001; 86: 3815-3819.
41. Weyer C, Funahashi T, Tanaka S, Hotta K, Matsuzawa Y, Pratley RE et al. Hypoadiponectinemia in obesity and Type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001; 86: 1930-1935.
42. Hotta K, Funahashi T, Bodkin NL, Ortmeyer HK, Arita Y, Hansen BC et al. Circulating concentrations of the adipocyte protein adiponectin are decreased in parallel with reduced insulin sensitivity during the progression to Type 2 diabetes in rhesus monkeys. Diabetes. 2001; 50: 1126-1133.
43. Yamauchi T, Kamon J, Waki H, Terauchi Y, Kubota N, Hara K et al. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med. 2001; 7: 941-946.
44. Abbasi F, Chu JW, Lamendola C, McLaughlin T, Hayden J, Reaven GM et al. Discrimination between obesity and insulin resistance in the relationship with adiponectin. Diabetes. 2004; 53: 585-590. (Pubitemid 38270626)
45. Lindsay RS, Funahashi T, Hanson RL, Matsuzawa Y, Tanaka S, Tataranni PA et al. Adiponectin and development of Type 2 diabetes in the Pima Indian population. Lancet. 2002; 360: 57-58.
46. Beltowski J. Adiponectin and resistin - new hormones of white adipose tissue. Med Sci Monit. 2003; 9: 55-61.
47. Iwashima Y, Katsuya T, Ishikawa K, Ouchi N, Ohishi M, Sugimoto K et al. Hypoadiponectinemia is an independent risk factor for hypertension. Hypertension. 2004; 43: 1318-1323.
48. Kazumi T, Kawaguchi A, Sakai K, Hirano T, Yoshino G. Young men with high-normal blood pressure have lower serum adiponectin, smaller LDLsize, and higher elevated heart rate than those with optimal blood pressure. Diabetes Care. 2002; 25: 971-976.
49. Yang WS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL et al. Plasma adiponectin levels in overweight and obese Asians. Obes Res. 2002; 10: 1104-1110.
50. Shatat IF, Freeman KD, Vuguin PM, Dimartino-Nardi JR, Flynn JT. Relationship between adiponectin and ambulatory blood pressure in obese adolescents. Pediatr Res. 2009; 65: 691-695.
51. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T et al. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endocrinol Metab. 2003; 88: 3236-3240.
52. Fernandez-Real JM, Castro A, Vazquez G, Casamitjana R, Lopez-Bermejo A, Penarroja G et al. Adiponectin is associated with vascular function independent of insulin sensitivity. Diabetes Care. 2004; 27: 739-745.
53. Ouchi N, Ohishi M, Kihara S, Funahashi T, Nakamura T, Nagaretani H et al. Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension. 2003; 42: 231-234.
54. Chandran M, Phillips SA, Ciaraldi T, Henry RR. Adiponectin: more than just another fat cell hormone? Diabetes Care. 2003; 26: 2442-2450.
55. Festa A, D'Agostino R, Jr, Howard G, Mykkanen L, Tracy RP, Haffner SM. Chronic subclinical inflammation as part of the insulin resistance syndrome: the insulin resistance atherosclerosis study (IRAS). Circulation. 2000; 102: 42-47.
56. Adamczak M, Wiecek A, Funahashi T, Chudek J, Kokot F, Matsuzawa Y. Decreased plasma adiponectin concentration in patients with essential hypertension. Am J Hypertens. 2003; 16: 72-75.
57. Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang WS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol Metab. 2003; 88: 4130-4134.
58. Watanabe S, Okura T, Kurata M, Irita J, Manabe S, Miyoshi K et al. The effect of losartan and amlodipine on serum adiponectin in Japanese adults with essential hypertension. Clin Ther. 2006; 28: 1677-1685.
59. Yilmaz MI, Sonmez A, Caglar K, Celik T, Yenicesu M, Eyileten T et al. Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome. Nephrology. (Carlton). 2007; 12: 147-153.
60. Nomura S, Shouzu A, Omoto S, Nishikawa M, Iwasaka T. Long-term treatment with nifedipine modulates procoagulant marker and C-C chemokine in hypertensive patients with Type 2 diabetes mellitus. Thromb Res. 2005; 115: 277-285.
61. Furuhashi M, Ura N, Higashiura K, Murakami H, Tanaka M, Moniwa N et al. Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension. 2003; 42: 76-81.
62. Ohashi K, Iwatani H, Kihara S, Nakagawa Y, Komura N, Fujita K et al. Exacerbation of albuminuria and renal fibrosis in subtotal renal ablation model of adiponectin-knockout mice. Arterioscler Thromb Vasc Biol. 2007; 27: 1910-1917.
63. Sharma K, Ramachandrarao S, Qiu G, Usui HK, Zhu Y, Dunn SR et al. Adiponectin regulates albuminuria and podocyte function in mice. J Clin Invest. 2008; 118: 1645-1656.
64. Lin J, Hu FB, Curhan G. Serum adiponectin and renal dysfunction in men with Type 2 diabetes. Diabetes Care. 2007; 30: 239-244.
65. Becker B, Kronenberg F, Kielstein JT, Haller H, Morath C, Ritz E et al. Renal insulin resistance syndrome, adiponectin and cardiovascular events in patients with kidney disease: the mild and moderate kidney disease study. J Am Soc Nephrol. 2005; 16: 1091-1098.
66. Kaisar MO, Armstrong K, Hawley C, Campbell S, Mudge D, Johnson DW et al. Adiponectin is associated with cardiovascular disease in male renal transplant recipients: baseline results from the LANDMARK 2 study. BMC Nephrol. 2009; 10: 29.
67. Bayes B, Lauzurica R, Granada ML, Serra A, Bonet J, Fontsere N et al. Adiponectin and risk of new-onset diabetes mellitus after kidney transplantation. Transplantation. 2004; 78: 26-30.
68. Adamczak M, Szotowska M, Chudek J, Karkoszka H, Cierpka L, Wiecek A. Plasma adiponectin concentration in patients after successful kidney transplantation - a single-center, observational study. Clin Nephrol. 2007; 67: 381-390.
69. Norata GD, Baragetti I, Raselli S, Stucchi A, Garlaschelli K, Vettoretti S et al. Plasma adiponectin levels in chronic kidney disease patients: relation with molecular inflammatory profile and metabolic status. Nutr Metab Cardiovasc Dis; 20: 56-63.
70. Chitalia N, Raja RB, Bhandara T, Agrawal P, Kaski JC, Jha V et al. Serum adiponectin and cardiovascular risk in chronic kidney disease and kidney transplantation. J Nephrol; 23: 77-84.
71. Zoccali C, Mallamaci F, Tripepi G, Benedetto FA, Cutrupi S, Parlongo S et al. Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease. J Am Soc Nephrol. 2002; 13: 134-141. (Pubitemid 34042020)
72. Nanayakkara PW, Le Poole CY, Fouque D, van Guldener C, Stehouwer CD, Smulders YM et al. Plasma adiponectin concentration has an inverse and a non linear association with estimated glomerular filtration rate in patients with K/DOQI 3 - 5 chronic kidney disease. Clin Nephrol. 2009; 72: 21-30.
73. Menon V, Li L, Wang X, Greene T, Balakrishnan V, Madero M et al. Adiponectin and mortality in patients with chronic kidney disease. J Am Soc Nephrol. 2006; 17: 2599-2606. (Pubitemid 44300977)
74. Ohashi N, Kato A, Misaki T, Sakakima M, Fujigaki Y, Yamamoto T et al. Association of serum adiponectin levels with all-cause mortality in hemodialysis patients. Intern Med. 2008; 47: 485-491.
75. Chudek J, Adamczak M, Karkoszka H, Budzinski G, Ignacy W, Funahashi T et al. Plasma adiponectin concentration before and after successful kidney transplantation. Transplant Proc. 2003; 35: 2186-2189.
76. Park SH, Carrero JJ, Lindholm B, Stenvinkel P. Adiponectin in chronic kidney disease has an opposite impact on protein-energy wasting and cardiovascular risk: two sides of the same coin. Clin Nephrol. 2009; 72: 87-96.
77. Rossi AS, Lombardo YB, Lacorte JM, Chicco AG, Rouault C, Slama G et al. Dietary fish oil positively regulates plasma leptin and adiponectin levels in sucrose-fed, insulin-resistant rats. Am J Physiol Regul Integr Comp Physiol. 2005; 289: 486-494.
78. Neschen S, Morino K, Rossbacher JC, Pongratz RL, Cline GW, Sono S et al. Fish oil regulates adiponectin secretion by a peroxisome proliferatoractivated receptor-gamma-dependent mechanism in mice. Diabetes. 2006; 55: 924-928.
79. Bensaid M, Gary-Bobo M, Esclangon A, Maffrand JP, Le Fur G, Oury-Donat F et al. The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol. 2003; 63: 908-914.
80. Miyazaki T, Shimada K, Mokuno H, Daida H. Adipocyte derived plasma protein, adiponectin, is associated with smoking status in patients with coronary artery disease. Heart. 2003; 89: 663.
81. Iwashima Y, Katsuya T, Ishikawa K, Kida I, Ohishi M, Horio T et al. Association of hypoadiponectinemia with smoking habit in men. Hypertension. 2005; 45: 1094-1100.
82. Swarbrick MM, Havel PJ. Physiological, pharmacological, and nutritional regulation of circulating adiponectin concentrations in humans. Metab Syndr Relat Disord. 2008; 6: 87-102.